NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
NRx Pharmaceuticals announced its intent to conduct an underwritten public offering of common stock to raise capital for working capital and general corporate purposes. BTIG, LLC is acting as lead bookrunner with Lucid Capital Markets as joint bookrunner; the underwriter holds a 30-day option to purchase up to 15% additional shares.
Key figures
- Overallotment option
- 15%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.